Advertisement


Ana Oaknin, MD, PhD, on Cervical Cancer: New Findings on Cemiplimab in Recurrent or Metastatic Disease

ESMO Congress 2022

Advertisement

Ana Oaknin, MD, PhD, of Barcelona’s Vall d’Hebron University Hospital, discusses an analysis of long-term survival from the EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial. Cemiplimab-rwlc is the first immunotherapy to demonstrate an overall survival benefit as a second-line monotherapy for patients with recurrent or metastatic cervical cancer previously treated with platinum-based chemotherapy but not immunotherapy. The benefit was sustained in this population (Abstract 519MO).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
EMPOWER-Cervical 1 is a Phase III open-label randomized clinical trial in patients with recurrent metastatic cervical cancer who have progress after platinum therapy. 608 patients were randomized to anti-PD1 agent cemiplimab of investigator choice chemotherapy. The main stratification factors were geography regions, previous use of bevacizumab, histology, and ECOG. Patients received therapy until progression and acceptable toxicity on 96 weeks. The primary endpoint of the study was overall survival, and secondary endpoint was PFS and overall response rate. Regarding baseline characteristics, the majority of patients had a squamous cell carcinoma less, than half had previous use of bevacizumab, and approximately 50% of the patients had received more than one prior line of therapy for the recovering and metastatic setting. The trial met its primary endpoint and the final analysis of survival, with 30 months of follow-up show that median overall survival was significantly longer with cemiplimab compared with chemotherapy in the squamous cell carcinoma population, also, in the overall population. Regarding the results, according the PDL-1 status, we can state that overall survival was longer for both populations, PDL-1-positive and PDL-1-negative. In addition, higher overall respond rates were observed with cemiplimab compared with chemotherapy in all the population, namely PDL-1-positive and PDL-1-negative. In terms of safety, there is no new safety signal. The safety profile of cemiplimab was consistent with that other anti PDL-1 regimen. So, we can conclude saying that cemiplimab, a second-line therapy after platinum failure statistically and clinically meaningful prolongation of overall survival compared with chemotherapy in squamous cell carcinoma population, and in the overall population. In the PDL-tested population, cemiplimab was associated with the clinical-meaningful improvement of overall survival compared with chemotherapy in both populations, namely PDL-1-positive and PDL-1-negative. In summary, cemiplimab was associated with a prolongation on overall survival for the patients who have progress after platinum therapy, regardless of PDL-1 status. I can summarize saying that with a median follow-up of three months, the final overall survival data for the EMPOWER-Cervical trial showed that cemiplimab was associated with significantly prolongation of overall survival for our patients with metastatic recurrent cervical cancer who have progress after platinum therapy.

Related Videos

Prostate Cancer

Neal D. Shore, MD, on Prostate Cancer: Biomarker Analysis, Enzalutamide, and Active Surveillance

Neal D. Shore, MD, of Carolina Urologic Research Center/Genesis Care, discusses new data from the ENACT trial, which showed that patients with prostate cancer and the RNA biomarkers PAM50 and AR-A were likely to have better outcomes with enzalutamide treatment. The results suggest that such RNA biomarkers may help to identify patients who may benefit from enzalutamide treatment compared with active surveillance (Abstract 1385P).

Breast Cancer

Matthew P. Goetz, MD, on Breast Cancer: Interim Survival Results With Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor

Matthew P. Goetz, MD, of Mayo Clinic, discusses recent data from the MONARCH 3 trial of patients with advanced hormone receptor–positive, HER2-negative breast cancer. The study, a second interim analysis, showed that longer overall survival was observed in both the intention-to-treat group as well as in the subgroup with visceral disease. However, neither met the threshold for statistical significance, and further analyses are planned when more data can be reported. (Abstract LBA15).

Lung Cancer
Immunotherapy

Gérard Zalcman, MD, PhD, on Non–Small Cell Lung Cancer: Phase III Trial Findings on Nivolumab and Ipilimumab

Gérard Zalcman, MD, PhD, of France’s Bichat-Claude Bernard Hospital, Assistance Publique–Hôpitaux de Paris, discusses phase III results from the IFCT-1701 trial, which explored the questions of whether to administer nivolumab plus ipilimumab for 6 months or whether to prolong the treatment in patients with advanced non–small cell lung cancer (Abstract 972O).

Lung Cancer
Immunotherapy

Martin Reck, MD, PhD, on NSCLC: New Findings on Cemiplimab, Nivolumab, and Ipilimumab

Martin Reck, MD, PhD, of Germany’s Lung Clinic Grosshansdorf, details two trials that included patients with advanced non–small cell lung cancer: 3-year survival outcomes in the EMPOWER-Lung 1 study of continued cemiplimab-rwlc beyond disease progression with the addition of chemotherapy, and phase III results from the IFCT-1701 trial of nivolumab plus ipilimumab 6-month treatment vs treatment continuation (LBA54 and Abstract 972O).

Lung Cancer

Tony S.K. Mok, MD, on NSCLC: Review of Recent Data From the SUNRISE and ORIENT-31 Trials

Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses two late-breaking abstracts presented at ESMO 2022: the phase II SUNRISE study, which compared sintilimab plus anlotinib vs platinum-based chemotherapy as first-line therapy in patients with metastatic non–small cell lung cancer (NSCLC); and the ORIENT-31 trial, which compared sintilimab with or without IBI305 (a bevacizumab biosimilar) plus chemotherapy in patients with EGFR-mutated nonsquamous NSCLC who experienced disease progression on EGFR tyrosine kinase inhibitors.

Advertisement

Advertisement




Advertisement